SCHEMBL6736376

SCHEMBL6736376

Cc1ccccc1N1CCN(Cl)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.60
ALDH1A1 P00352 2/20 0.53
HPGD P15428 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
LMNA P02545 1/20 0.53
MCOLN3 Q8TDD5 1/20 0.53
AKR1C3 P42330 1/20 0.50
SLC18A3 Q16572 1/20 0.50
ATM Q13315 3/20 0.49
KMT2A Q03164 1/20 0.49
HTR7 P34969 2/20 0.47
TSHR P16473 1/20 0.47
AR P10275 2/20 0.46
NPC1 O15118 1/20 0.46
RECQL P46063 1/20 0.46
HSD11B1 P28845 1/20 0.45
HTT P42858 1/20 0.45
ADRA1D P25100 1/20 0.45
ADRA1A P35348 1/20 0.45
ADRA1B P35368 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4291189 0.89 ADRB1 (0.72) ADRB1ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL173027 0.81 ADRB1 (0.62) ADRB1ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL30656303 0.81 ADRB1 (0.62) ADRB1ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL10118836 0.80 ADRB1 (0.61) ADRB1ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL329301 0.80 ADRB1 (0.67) ADRB1ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL10679708 0.79 ADRB1 (0.60) ADRB1ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL11206795 0.79 ADRB1 (0.60) ADRB1ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL28587090 0.79 ADRB1 (0.60) ADRB1ALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL18408991 0.79 ADRB1 (0.60) ADRB1ALDH1A1HPGDSMN1; SMN2LMNA
Ammonia Solution, Strong SCHEMBL28721086 0.79 ADRB1 (0.60) ADRB1ALDH1A1HPGDSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040186170-A1 Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient EGIS GYOGYSZERGYAR (HU) 2004-09-23 US disclosed
EP-1077973-A2 BENZOFURAN DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND A PROCESS FOR THE PREPARATION OF THE ACTIVE INGREDIENT EGIS GYOGYSZERGYAR RT. (HU) 2001-02-28 EP disclosed
WO-1999058527-A2 BENZOFURAN DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND A PROCESS FOR THE PREPARATION OF THE ACTIVE INGREDIENT EGIS Gyógyszergyár Rt. (HU) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186170-A1 Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient CYP2F1, CYP3A4, CYP2S1 ADRB1 243/4885ALDH1A1 81/4885HPGD 376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.